Table 2. Case – control study of MYD88 c.T778C detection by NGS.
| PCNSL | Control | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no | Tumor DNA | Circulating tumor DNA | Circulating tumor DNA | |||||||||||
| Age (y) | MYD88 c.T778C | Percentage of tumor cell | MAF (%) | Reads number | MAF (%) | Reads number | MYD88 c.T778C | Age (y) | Histology | MAF (%) | Reads number | MYD88 c.T778C | Concentration (ng/ml) | |
| #13 | 49 | Pos | >50% | 60.09 | 134/223 | 0.6 | 143/23708 | Pos | 31 | GBM | <0.5 | 74/48876 | Neg | 41.2 |
| #28 | 53 | Pos | >50% | 25.56 | 23/90 | <0.5 | 18/8958 | Neg | 52 | GBM | <0.5 | 48/42009 | Neg | 65.2 |
| #22 | 53 | Pos | >50% | 43.92 | 159/362 | <0.5 | 24/23898 | Neg | 55 | GBM | <0.5 | 61/40962 | Neg | 54.4 |
| #16 | 57 | Pos | >50% | 43.48 | 70/161 | <0.5 | 49/42713 | Neg | 58 | GBM | <0.5 | 56/47997 | Neg | 43.2 |
| #44 | 60 | Neg | >50% | - | - | <0.5 | 33/22877 | Neg | 59 | CRC | <0.5 | 70/42143 | Neg | 128 |
| #12 | 61 | Pos | >50% | 47.5 | 76/160 | <0.5 | 62/20731 | Neg | 61 | CRC | <0.5 | 94/53803 | Neg | 53.6 |
| #19 | 61 | Pos | 25% | 26.58 | 21/79 | <0.5 | 16/17867 | Neg | 61 | GBM | <0.5 | 91/57498 | Neg | 20.1 |
| #48 | 62 | Pos | >50% | 7.58 | 21/277 | <0.5 | 6/5848 | Neg | 62 | CRC | <0.5 | 56/50644 | Neg | 69.2 |
| #8 | 63 | Pos | >50% | 28.48 | 94/330 | 11.2 | 5146/46074 | Pos | 62 | GBM | <0.5 | 45/38929 | Neg | 54.8 |
| #1 | 63 | Neg | >50% | - | - | <0.5 | 36/26209 | Neg | 63 | CRC | <0.5 | 78/49144 | Neg | 53.2 |
| #27 | 63 | Pos | 25% | 15.6 | 17/109 | <0.5 | 59/31514 | Neg | 63 | CRC | <0.5 | 54/50353 | Neg | 52.4 |
| #18 | 64 | Pos | >50% | 44.03 | 70/159 | <0.5 | 23/25640 | Neg | 65 | GBM | <0.5 | 78/59889 | Neg | 25.6 |
| #26 | 65 | Pos | >50% | 54 | 189/350 | 28.7 | 14356/49954 | Pos | 65 | GBM | <0.5 | 67/59691 | Neg | 40.8 |
| #2 | 67 | Neg | >50% | - | - | <0.5 | 9/14377 | Neg | 67 | CRC | <0.5 | 63/29102 | Neg | 120 |
| #25 | 68 | Pos | 25-50% | 67.74 | 147/217 | <0.5 | 39/32563 | Neg | 68 | CRC | <0.5 | 65/56826 | Neg | 44.8 |
| #42 | 68 | Pos | >50% | 24.1 | 60/249 | <0.5 | 64/60828 | Neg | 69 | CRC | <0.5 | 84/56066 | Neg | 55.6 |
| #15 | 69 | Neg | >50% | - | - | <0.5 | 74/42979 | Neg | 71 | GBM | <0.5 | 57/28504 | Neg | 54 |
| #5 | 71 | Pos | 25-50% | 91.12 | 359/394 | 7.7 | 3401/44285 | Pos | 72 | CRC | <0.5 | 48/34430 | Neg | 72 |
| #46 | 71 | Neg | 25-50% | - | - | <0.5 | 42/38638 | Neg | 72 | CRC | <0.5 | 53/57963 | Neg | 57.6 |
| #24 | 74 | Neg | >50% | - | - | <0.5 | 49/27303 | Neg | 75 | GBM | <0.5 | 70/44478 | Neg | 35.52 |
| #21 | 77 | Pos | >50% | 67.31 | 313/465 | <0.5 | 48/27004 | Neg | 75 | GBM | <0.5 | 81/50177 | Neg | 43.6 |
| #11 | 78 | Neg | - | - | <0.5 | 82/35998 | Neg | 79 | CRC | <0.5 | 53/32229 | Neg | 117.6 | |
| #14 | 82 | Pos | 25-50% | 67.27 | 37/55 | 0.5 | 91/18056 | Pos | 81 | GBM | <0.5 | 46/52808 | Neg | 42.8 |
| #40 | 82 | Pos | 25% | 97.43 | 341/350 | 0.5 | 131/25528 | Pos | 82 | CRC | <0.5 | 59/47827 | Neg | 39.2 |
| #32 | 87 | Neg | >50% | - | - | <0.5 | 26/37256 | Neg | 85 | CRC | <0.5 | 60/49963 | Neg | 55.2 |
CRC: colorectal cancer; GBM: glioblastoma multiforme; MAF: mutant allele frequency; neg: negative; pos: positive; y: years.